Inventor · disambiguated record

Michael D. Kaufman

Also filed as: KAUFMAN MICHAEL D

44 granted patents·26 pending applications·1,636 citations·filing 2007–2025

99Inventor score

Technology areasA61P C07D A61K C07B C07K

Files withDECIPHERA PHARMACEUTICALS LLC53 FLYNN DANIEL L14 DECIPHERA PHARMACEUTICALS INC1 LATIGO BIOTHERAPEUTICS INC1 LILLY CO ELI1

Top patents by PatentIndex Score

70 records

0198US11793795B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Oct 24, 2023·13 cites·10 claims
0298US11612591B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Granted Mar 28, 2023·31 cites·11 claims
0398US11576903B2Amorphous kinase inhibitor formulations and methods of use thereofDECIPHERA PHARMACEUTICALS LLC·Filed 2021·Granted Feb 14, 2023·31 cites·12 claims
0498US11395818B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2021·Granted Jul 26, 2022·36 cites·3 claims
0598US11185535B2Amorphous kinase inhibitor formulations and methods of use thereofDECIPHERA PHARMACEUTICALS LLC·Filed 2021·Granted Nov 30, 2021·39 cites·1 claims
0698USRE48731EDihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseasesDECIPHERA PHARMACEUTICALS LLC·Filed 2019·Granted Sep 14, 2021·36 cites·21 claims
0798US9012635B2Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activitiesDECIPHERA PHARMACEUTICALS LLC·Filed 2014·Granted Apr 21, 2015·61 cites·34 claims
0898US8637672B2Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activitiesFLYNN DANIEL L·Filed 2012·Granted Jan 28, 2014·65 cites·19 claims
0998US8461179B1Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseasesFLYNN DANIEL L·Filed 2012·Granted Jun 11, 2013·102 cites·15 claims
1097US11801237B2Amorphous kinase inhibitor formulations and methods of use thereofDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Oct 31, 2023·13 cites·2 claims
1197US9387202B2Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activitiesDECIPHERA PHARMACEUTICALS LLC·Filed 2014·Granted Jul 12, 2016·60 cites·2 claims
1297US9309224B2N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activitiesDECIPHERA PHARMACEUTICALS LLC·Filed 2014·Granted Apr 12, 2016·60 cites·40 claims
1397US9187474B2Raf inhibitor compoundsDECIPHERA PHARMACEUTICALS LLC·Filed 2013·Granted Nov 17, 2015·60 cites·19 claims
1497US8921565B2Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activitiesFLYNN DANIEL L·Filed 2012·Granted Dec 30, 2014·62 cites·23 claims
1597US8569319B2Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activitiesFLYNN DANIEL L·Filed 2011·Granted Oct 29, 2013·62 cites·23 claims
1697US8486951B2Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activitiesFLYNN DANIEL L·Filed 2012·Granted Jul 16, 2013·61 cites·14 claims
1797US8278331B2N-acyl ureas exhibiting anti-cancer and anti-proliferative activitiesFLYNN DANIEL L·Filed 2009·Granted Oct 2, 2012·65 cites·7 claims
1897US8188113B2Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseasesFLYNN DANIEL L·Filed 2007·Granted May 29, 2012·74 cites·19 claims
1997US7897762B2Kinase inhibitors useful for the treatment of proliferative diseasesDECIPHERA PHARMACEUTICALS LLC·Filed 2007·Granted Mar 1, 2011·59 cites·93 claims
2097US7790756B2Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseasesDECIPHERA PHARMACEUTICALS LLC·Filed 2007·Granted Sep 7, 2010·79 cites·22 claims
2196US9193719B21,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activitiesDECIPHERA PHARMACEUTICALS LLC·Filed 2014·Granted Nov 24, 2015·60 cites·36 claims
2296US9181223B22-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activitiesDECIPHERA PHARMACEUTICALS LLC·Filed 2014·Granted Nov 10, 2015·62 cites·29 claims
2396US9133183B2Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activitiesDECIPHERA PHARMACEUTICALS LLC·Filed 2014·Granted Sep 15, 2015·60 cites·32 claims
2496US8940756B2Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseasesDECIPHERA PHARMACEUTICALS INC·Filed 2013·Granted Jan 27, 2015·73 cites·21 claims
2596US8143293B2Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseasesFLYNN DANIEL L·Filed 2008·Granted Mar 27, 2012·60 cites·22 claims
2695US12509443B2CSF-1R inhibitors and methods of use thereofDECIPHERA PHARMACEUTICALS LLC·Filed 2025·Granted Dec 30, 2025·1 cites·21 claims
2795US9457019B2Methods for inhibiting tie-2 kinase useful in the treatment of cancerDECIPHERA PHARMACEUTICALS LLC·Filed 2014·Granted Oct 4, 2016·70 cites·42 claims
2895US9382228B2N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activitiesDECIPHERA PHARMACEUTICALS LLC·Filed 2014·Granted Jul 5, 2016·60 cites·43 claims
2995US9334267B2RAF inhibitor compoundsDECIPHERA PHARMACEUTICALS LLC·Filed 2013·Granted May 10, 2016·60 cites·17 claims
3093US12226406B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2024·Granted Feb 18, 2025·0 cites·13 claims
3193US8741911B2Raf inhibitor compoundsLILLY CO ELI·Filed 2013·Granted Jun 3, 2014·61 cites·22 claims
3292US12318374B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2024·Granted Jun 3, 2025·0 cites·24 claims
3392US12213968B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2024·Granted Feb 4, 2025·0 cites·18 claims
3492US12213967B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2024·Granted Feb 4, 2025·0 cites·11 claims
3592US2025387380A1Amorphous kinase inhibitor formulations and methods of use thereofDECIPHERA PHARMACEUTICALS LLC·Filed 2025·Application pending·0 cites
3691US12064422B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Aug 20, 2024·0 cites·20 claims
3790US12023328B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Jul 2, 2024·0 cites·12 claims
3890US11969415B1(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Apr 30, 2024·0 cites·12 claims
3990US11918564B1Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Mar 5, 2024·0 cites·4 claims
4090US11911370B1Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Feb 27, 2024·0 cites·12 claims
4190US11903933B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Feb 20, 2024·0 cites·15 claims
4290US11850240B1Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Dec 26, 2023·0 cites·3 claims
4390US11850241B1Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Dec 26, 2023·0 cites·12 claims
4489US11844788B1Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Granted Dec 19, 2023·0 cites·12 claims
4587US11896585B2Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylureaDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Granted Feb 13, 2024·0 cites·5 claims
4683US2024197696A1Amorphous kinase inhibitor formulations and methods of use thereofDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Application pending·0 cites
4779US2022370423A1Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alphaDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Application pending·0 cites
4878US2022370424A1Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alphaDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Application pending·0 cites
4978US2022265622A1Amorphous kinase inhibitor formulations and methods of use thereofDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Application pending·0 cites
5078US2022265623A1Amorphous kinase inhibitor formulations and methods of use thereofDECIPHERA PHARMACEUTICALS LLC·Filed 2022·Application pending·0 cites

Showing the top 50 of 70 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when Michael D. Kaufman files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →